



Ref: Syn/CS/SE/2025-26/Apr/01

**Syngene International Limited**  
Biocon SEZ, Biocon Park, Plot No. 2 &  
3, Bommasandra Industrial Area, IV  
Phase, Jigani Link Road, Bengaluru  
560 099, Karnataka, India  
T +91 80 6891 8000  
F +91 80 6891 8808  
CIN: L85110KA1993PLC014937  
[www.syngeneintl.com](http://www.syngeneintl.com)

April 1, 2025

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
<b>Scrip Code: 539268</b>	<b>Scrip Symbol: SYNGENE</b>

**Sub: Intimation of appointment of Mr. Peter Bains as an Additional Director, designated as Managing Director & Chief Executive Officer.**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 (“SEBI Listing Regulations”), we wish to inform you that the Board of Directors, pursuant to the recommendation of the Nomination and Remuneration Committee (‘NRC’), approved the appointment of Mr. Peter Bains as an Additional Director, designated as Managing Director & Chief Executive Officer (a Key Managerial Personnel) of the Company effective April 1, 2025 subject to the approval of the shareholders of the Company.

In accordance with SEBI letter dated June 14, 2018 read along with NSE Circular dated June 20, 2018, having ref no. as - NSE/CML/2018/24, we hereby confirm that Mr. Peter Bains is not debarred from holding the office of director by virtue of any order of SEBI or any other authority.

The details as required under Regulation 30 read with Schedule III of the SEBI Listing Regulations, SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed in **Annexure 1**.

The above information will also be made available on the website of the Company at [www.syngeneintl.com](http://www.syngeneintl.com).

Kindly take the above information on record.

Thanking You

Yours faithfully,

**For SYNGENE INTERNATIONAL LIMITED**

\_\_\_\_\_  
Priyadarshini Mahapatra

**Head Legal, Company Secretary & Compliance Officer**

Encl: a/a

Details under Regulation 30 of the SEBI Listing Regulations read along with SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 :

Sr. No.	Particulars	Details
1.	Reason for change (viz. appointment, <del>re-appointment,</del> resignation, <del>removal,</del> death or otherwise)	Appointment as an Additional Director, designated as Managing Director & Chief Executive Officer(a Key Managerial Personnel).
2.	Date of appointment/ <del>re-appointment/cessation</del> (as applicable) & term of appointment/re-appointment;	Appointment with effect from April 1, 2025 for a period of 2 years.
3.	Brief profile	Brief profile attached as <b>Annexure 1A</b>
4.	Disclosure of relationship (in case of appointment)	None.

**Brief Profile of Mr. Peter Bains:**

Mr. Peter Bains, 67 years, holds a bachelor's degree in Science (Combined honours in Zoology and Physiology) from University of Sheffield, United Kingdom. He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels with an extensive track record of leadership and success in building companies, businesses, teams and brands for over 30 years. Mr. Bains brings in differentiating characteristics with extensive experience in Biopharmaceuticals across business and technology segmentation (Biotech, Vaccines, Branded Generics, Life Sciences, CRO) and geography encompassing both developed and emerging markets.

Mr. Bains had served as the Chief Executive Officer (CEO) and Member of the Board of Syngene International Limited for nearly six years, starting in 2010. During his tenure, he successfully led the company to its public listing in 2015. He joined back the Biocon Group as an Independent Director in Biocon Limited in December 2022 and later was appointed as the Group CEO in September 2023. He also held the position of CEO at Sosei Group, a publicly traded biopharmaceutical company in Japan. Prior to these roles, Mr. Bains had a distinguished 23-year career at GlaxoSmithKline (GSK), where he held several senior positions, including Head of Global Marketing and Senior Vice President of Commercial Development for GSK's International region.